KR102788829B1 - 야누스 키나제 억제제의 결정질 형태 - Google Patents

야누스 키나제 억제제의 결정질 형태 Download PDF

Info

Publication number
KR102788829B1
KR102788829B1 KR1020197017128A KR20197017128A KR102788829B1 KR 102788829 B1 KR102788829 B1 KR 102788829B1 KR 1020197017128 A KR1020197017128 A KR 1020197017128A KR 20197017128 A KR20197017128 A KR 20197017128A KR 102788829 B1 KR102788829 B1 KR 102788829B1
Authority
KR
South Korea
Prior art keywords
delete delete
respect
composition
crystalline form
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017128A
Other languages
English (en)
Korean (ko)
Other versions
KR20190092440A (ko
Inventor
유키히로 가미야
노리아키 시모야마
류헤이 오쿠라
사토루 노지
Original Assignee
니뽄 다바코 산교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 다바코 산교 가부시키가이샤 filed Critical 니뽄 다바코 산교 가부시키가이샤
Publication of KR20190092440A publication Critical patent/KR20190092440A/ko
Application granted granted Critical
Publication of KR102788829B1 publication Critical patent/KR102788829B1/ko
Assigned to 시오노기세야쿠 가부시키가이샤 reassignment 시오노기세야쿠 가부시키가이샤 권리의 전부이전등록 Assignors: 니뽄 다바코 산교 가부시키가이샤
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197017128A 2016-12-21 2017-12-20 야누스 키나제 억제제의 결정질 형태 Active KR102788829B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437,262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Publications (2)

Publication Number Publication Date
KR20190092440A KR20190092440A (ko) 2019-08-07
KR102788829B1 true KR102788829B1 (ko) 2025-03-31

Family

ID=60991475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017128A Active KR102788829B1 (ko) 2016-12-21 2017-12-20 야누스 키나제 억제제의 결정질 형태

Country Status (13)

Country Link
US (1) US11339181B2 (cg-RX-API-DMAC10.html)
EP (1) EP3559003B1 (cg-RX-API-DMAC10.html)
JP (3) JP2020502224A (cg-RX-API-DMAC10.html)
KR (1) KR102788829B1 (cg-RX-API-DMAC10.html)
CN (2) CN110325536A (cg-RX-API-DMAC10.html)
AU (1) AU2017380213B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019012210A2 (cg-RX-API-DMAC10.html)
CA (1) CA3044771A1 (cg-RX-API-DMAC10.html)
ES (1) ES2926986T3 (cg-RX-API-DMAC10.html)
IL (1) IL267393B2 (cg-RX-API-DMAC10.html)
MX (1) MX386181B (cg-RX-API-DMAC10.html)
TW (1) TWI822666B (cg-RX-API-DMAC10.html)
WO (1) WO2018117153A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
JP7597714B2 (ja) * 2019-08-07 2024-12-10 ロート製薬株式会社 涙液分泌促進用眼科組成物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
AU2024229918A1 (en) * 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500666A (ja) * 2005-07-07 2009-01-08 トムソン ライセンシング 対応スタンドを備えたフラット画面ディスプレイシステム
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
BRPI1012108B8 (pt) * 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo

Also Published As

Publication number Publication date
CN121045220A (zh) 2025-12-02
US20200017527A1 (en) 2020-01-16
BR112019012210A2 (pt) 2019-11-12
KR20190092440A (ko) 2019-08-07
CN110325536A (zh) 2019-10-11
JP2023024729A (ja) 2023-02-16
MX2019007462A (es) 2019-08-29
EP3559003B1 (en) 2022-08-24
JP2024161449A (ja) 2024-11-19
AU2017380213B2 (en) 2022-01-06
RU2019122566A3 (cg-RX-API-DMAC10.html) 2021-12-22
MX386181B (es) 2025-03-18
US11339181B2 (en) 2022-05-24
IL267393B2 (en) 2023-07-01
TW201829423A (zh) 2018-08-16
WO2018117153A1 (en) 2018-06-28
EP3559003A1 (en) 2019-10-30
JP2020502224A (ja) 2020-01-23
IL267393A (en) 2019-08-29
ES2926986T3 (es) 2022-10-31
IL267393B1 (en) 2023-03-01
AU2017380213A1 (en) 2019-05-23
TWI822666B (zh) 2023-11-21
RU2019122566A (ru) 2021-01-22
CA3044771A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP2024161449A (ja) ヤヌスキナーゼ阻害剤の結晶形
EP4166552B1 (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
CA2926845C (en) Salt and crystal forms of plk-4 inhibitor
EP3286190B1 (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)
KR101804749B1 (ko) 히스타민 ｈ3 수용체 길항제의 신규 푸마레이트 염
EP3286189B1 (en) Crystalline mesylate salt as semicarbazide-sensitive amine oxidase (ssao) enzyme inhibitor
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
JP2026509019A (ja) 抗ウイルスプロドラッグの結晶形成
SG11202111003UA (en) Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
KR20250038235A (ko) 고체 형태의 jak 억제제 및 이의 제조 공정
TW202334120A (zh) 經取代之哌啶化合物之結晶以及經取代之哌啶化合物之鹽及其等之結晶
US12065441B2 (en) Pyrazolopyrimidine derivative, use thereof and pharmaceutical composition
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
KR20150129698A (ko) 피롤리딘-3-일 아세트산 유도체의 염 및 그의 결정
US10822336B2 (en) Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição
WO2023008470A1 (ja) 縮環アミン誘導体
HK40057216A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
HK1249906B (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)